295 related articles for article (PubMed ID: 25706990)
1. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.
Brendel M; Jaworska A; Grießinger E; Rötzer C; Burgold S; Gildehaus FJ; Carlsen J; Cumming P; Baumann K; Haass C; Steiner H; Bartenstein P; Herms J; Rominger A
PLoS One; 2015; 10(2):e0116678. PubMed ID: 25706990
[TBL] [Abstract][Full Text] [Related]
2. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
3. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
4. [
Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
[TBL] [Abstract][Full Text] [Related]
6. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal evaluation of a novel BChE PET tracer as an early
Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J
Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675
[No Abstract] [Full Text] [Related]
8. Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer's disease with PET imaging agents
Son HJ; Jeong YJ; Yoon HJ; Lee SY; Choi GE; Park JA; Kim MH; Lee KC; Lee YJ; Kim MK; Cho K; Kang DY
BMC Neurosci; 2018 Jul; 19(1):45. PubMed ID: 30053803
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.
Brendel M; Jaworska A; Herms J; Trambauer J; Rötzer C; Gildehaus FJ; Carlsen J; Cumming P; Bylund J; Luebbers T; Bartenstein P; Steiner H; Haass C; Baumann K; Rominger A
Mol Psychiatry; 2015 Oct; 20(10):1179-87. PubMed ID: 26055427
[TBL] [Abstract][Full Text] [Related]
10. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical study on [
Xu M; Guo J; Gu J; Zhang L; Liu Z; Ding L; Fu H; Ma Y; Liang S; Wang H
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):652-663. PubMed ID: 34292345
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
[TBL] [Abstract][Full Text] [Related]
13. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
[TBL] [Abstract][Full Text] [Related]
14. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
[TBL] [Abstract][Full Text] [Related]
16. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with
Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S
J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994
[TBL] [Abstract][Full Text] [Related]
17. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study.
Brendel M; Probst F; Jaworska A; Overhoff F; Korzhova V; Albert NL; Beck R; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Kleinberger G; Haass C; Herms J; Rominger A
J Nucl Med; 2016 Jun; 57(6):954-60. PubMed ID: 26912428
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
19. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
[TBL] [Abstract][Full Text] [Related]
20. Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.
Jennings D; Seibyl J; Sabbagh M; Lai F; Hopkins W; Bullich S; Gimenez M; Reininger C; Putz B; Stephens A; Catafau AM; Marek K
Neurology; 2015 Feb; 84(5):500-7. PubMed ID: 25568295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
